{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:34:21Z","timestamp":1781177661683,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020152","name":"Madrigal Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s12325-024-02979-7","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T04:01:43Z","timestamp":1727323303000},"page":"4335-4355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Progression from Non-alcoholic Steatohepatitis to Advanced Liver Diseases and Mortality Among Medicare Patients"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0263-9384","authenticated-orcid":false,"given":"Yestle","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Medicis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Nunag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"2979_CR1","unstructured":"American Liver Foundation. Nonalcoholic Fatty Liver Disease (NAFLD). Available from: https:\/\/liverfoundation.org\/for-patients\/about-the-liver\/diseases-of-the-liver\/non-alcoholic-fatty-liver-disease\/. Accessed 25 July 2024."},{"key":"2979_CR2","unstructured":"American Liver Foundation. Nash Complications. Available from: https:\/\/liverfoundation.org\/for-patients\/about-the-liver\/diseases-of-the-liver\/nonalcoholic-steatohepatitis-information-center\/nash-complications\/. Accessed 25 July 2024."},{"issue":"4","key":"2979_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10198-020-01256-y","volume":"22","author":"A Morgan","year":"2021","unstructured":"Morgan A, Hartmanis S, Tsochatzis E, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. Eur J Health Econ. 2021;22(4):505\u201318. https:\/\/doi.org\/10.1007\/s10198-020-01256-y.","journal-title":"Eur J Health Econ"},{"key":"2979_CR4","doi-asserted-by":"crossref","unstructured":"Fishman J, O'Connell T, Parrinello CM, et al. Prevalence of nonalcoholic steatohepatitis and associated fibrosis stages among US adults, using imaging- vs biomarker-based non-invasive tests. JHEOR. 2024.","DOI":"10.36469\/jheor.2024.92223"},{"issue":"11","key":"2979_CR5","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/apt.15679","volume":"51","author":"R Loomba","year":"2020","unstructured":"Loomba R, Wong R, Fraysse J, et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment Pharmacol Ther. 2020;51(11):1149\u201359. https:\/\/doi.org\/10.1111\/apt.15679.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2979_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.eprac.2021.12.010","volume":"28","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Henry L. Fatty liver through the ages: nonalcoholic steatohepatitis. Endocr Pract. 2022;28(2):204\u201313. https:\/\/doi.org\/10.1016\/j.eprac.2021.12.010.","journal-title":"Endocr Pract"},{"issue":"6","key":"2979_CR7","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/hep.30946","volume":"70","author":"R Loomba","year":"2019","unstructured":"Loomba R, Adams LA. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology. 2019;70(6):1885\u20138. https:\/\/doi.org\/10.1002\/hep.30946.","journal-title":"Hepatology"},{"key":"2979_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells10081917","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee S, Kar A, Khatun N, et al. Familiarity Breeds Strategy: In Silico Untangling of the Molecular Complexity on Course of Autoimmune Liver Disease-to-Hepatocellular Carcinoma Transition Predicts Novel Transcriptional Signatures. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10081917.","journal-title":"Cells"},{"issue":"1","key":"2979_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2023-100036","volume":"2","author":"C Binxia","year":"2024","unstructured":"Binxia C, Hui T, Ang H, et al. Prevalence and prediction of hepatocellular carcinoma in alcohol-associated liver disease: a retrospective study of 136 571 patients with chronic liver diseases. EGastroenterology. 2024;2(1): e100036. https:\/\/doi.org\/10.1136\/egastro-2023-100036.","journal-title":"EGastroenterology."},{"issue":"1","key":"2979_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1665-2681(19)30803-8","volume":"14","author":"R Zampino","year":"2015","unstructured":"Zampino R, Pisaturo MA, Cirillo G, et al. Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. Ann Hepatol. 2015;14(1):75\u201382. https:\/\/doi.org\/10.1016\/S1665-2681(19)30803-8.","journal-title":"Ann Hepatol"},{"issue":"1","key":"2979_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12876-020-01240-z","volume":"20","author":"P Pitisuttithum","year":"2020","unstructured":"Pitisuttithum P, Chan WK, Piyachaturawat P, et al. Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study. BMC Gastroenterol. 2020;20(1):88. https:\/\/doi.org\/10.1186\/s12876-020-01240-z.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"2979_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/poh2.31","volume":"1","author":"P Pitisuttithum","year":"2022","unstructured":"Pitisuttithum P, Treeprasertsuk S. Nonalcoholic fatty liver disease (NAFLD) among older adults. Portal Hypertens Cirrhosis. 2022;1(3):184\u201391. https:\/\/doi.org\/10.1002\/poh2.31.","journal-title":"Portal Hypertens Cirrhosis"},{"key":"2979_CR13","unstructured":"U.S. Food & Drug Administration. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. March 14, 2024. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease. Accessed 25 July 2024."},{"key":"2979_CR14","unstructured":"Madrigal Pharmaceuticals Inc. Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra\u2122 (resmetirom) Presented at the EASL Congress. Globe Newswire. Conshohocken, PA. June 06, 2024. Available from: https:\/\/ir.madrigalpharma.com\/news-releases\/news-release-details\/madrigal-pharmaceuticals-announces-new-data-phase-3-maestro-nash. Accessed 25 July 2024."},{"key":"2979_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3532","volume":"363","author":"SM Langan","year":"2018","unstructured":"Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ (Clinical research ed). 2018;363: k3532. https:\/\/doi.org\/10.1136\/bmj.k3532.","journal-title":"BMJ (Clinical research ed)"},{"issue":"7","key":"2979_CR16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/pds.3290","volume":"21","author":"D Goldberg","year":"2012","unstructured":"Goldberg D, Lewis J, Halpern S, Weiner M, Lo Re 3rd V. Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf. 2012;21(7):765\u20139. https:\/\/doi.org\/10.1002\/pds.3290.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2979_CR17","unstructured":"Chronic Conditions Warehouse Virtual Research Data Center. Data Output Review Process. 2023."},{"key":"2979_CR18","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.24069","author":"JC Fishman","year":"2024","unstructured":"Fishman JC, Qian C, Kim Y, et al. Cost burden of cirrhosis and liver disease progression in metabolic dysfunction-associated steatohepatitis: a US cohort study. J Manag Care Specialty Pharm. 2024. https:\/\/doi.org\/10.18553\/jmcp.2024.24069.","journal-title":"J Manag Care Specialty Pharm"},{"issue":"4","key":"2979_CR19","doi-asserted-by":"publisher","first-page":"562","DOI":"10.14309\/ajg.0000000000000484","volume":"115","author":"SC Gordon","year":"2020","unstructured":"Gordon SC, Fraysse J, Li S, Ozbay AB, Wong RJ. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients. Am J Gastroenterol. 2020;115(4):562\u201374. https:\/\/doi.org\/10.14309\/ajg.0000000000000484.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2979_CR20","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jhep.2022.07.004","volume":"77","author":"AM Allen","year":"2022","unstructured":"Allen AM, Therneau TM, Ahmed OT, et al. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. J Hepatol. 2022;77(5):1237\u201345. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.004.","journal-title":"J Hepatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02979-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02979-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02979-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T19:12:11Z","timestamp":1729019531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02979-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2979"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02979-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yestle Kim and Joe Medicis are employees of Madrigal Pharmaceuticals and may own stocks\/and or options from Madrigal Pharmaceuticals. Matthew Davis and Dominic Nunag are employees of Medicus Economics, LLC. Medicus Economics, LLC received consulting fees for research from Madrigal Pharmaceuticals. Robert Gish has performed as Consultant and\/or Advisor to (in the last two years): Abacus, Abbott, AbbVie, Albireo, Aligos, Altimunne, Arrowhead, AstraZeneca, Audentes Therapeutics, Corcept, Dynavax, Effectus, Eiger, Eisai, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, GlaxoSmithKline, Helios, HepaTX, HepQuant, Intercept, Janssen, JBS Science, Kinnate Bio, Madrigal, Merck, Precision BioSciences, Pfizer, Seres Therapeutics, Topography Health, Tune Therapeutics, Venatorx, Virion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"An Institutional Review Board exemption was not required for this study as the data were de-identified and compliant with Health Insurance Portability and Accountability Act regulations. This study was conducted according to best practices recommended by the Reporting of Studies Conducted Using Observational Routinely Collected Data for Pharmacoepidemiology (RECORD-PE) guidelines []. This study was performed in accordance with the ethical guidelines of the 1964 Declaration of Helsinki and its subsequent updates. Database permission was provided by CMS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}